Q3 2026 Vanda Pharmaceuticals Inc. Earnings Conference Call - VANDA PHARMACEUTICALS INC

Financial Performance:

• Q3 2026 total revenue reached $69.8 million, a 24% year-over-year (YoY) increase and 38% sequential increase; first nine months 2026 revenue totaled $172.1 million (8% YoY growth).
• Net loss for Q3 2026 was $22.6 million, significantly improved from $62.5 million in Q2 2026, driven by $19.3M revenue growth and $21M operating expense reduction.
• First nine months 2026 net loss was $133.6 million compared to $79.3 million in 2025, including a one-time non-cash tax charge of $21.4 million valuation allowance in 2025.
• Operating expenses decreased 18% sequentially to $93.3 million in Q3 2026 (from $114.3 million in Q2), driven by concluding Phase 3 and launch preparation activities.
• Cash position stood at $140.5 million as of September 30, 2026, a decrease of $123.4 million from year-end 2025, impacted by a $10 million milestone payment to Eli Lilly and commercial launch costs.
• Revenue mix: FNAPT sales grew 24% to $104.3M (YTD); Hetlios sales declined 21% to $43.2M (YTD) due to generic competition; Ponvori sales rose 11% to $21.9M (YTD); Nereus contributed $2.6M (YTD) since May 2026 launch.

Guidance and Future Outlook:

• Updated full-year 2026 revenue guidance to >$240 million, driven by FNAPT, Nereus, and upcoming Bisanti launch; Nereus expected to generate < $10 million in 2026 due to early-stage adoption.
• No cash burn guidance provided for 2026, though cash burn is expected to exceed 2025 levels as commercialization and development activities conclude.
• Operating expenses are expected to decrease further in future quarters as commercial launch preparations and Phase 3 activities wind down.
• Bisanti commercial launch is targeted for Q4 2026; Quimilza BLA has a PDUFA date of December 12, 2026, with commercial availability anticipated in the first half of 2027.
• Dysante (MDD) Phase 3 results expected in H1 2027; Hetlios SNDA for DSW-PD and Nereus SNDA for GLP-1 vomiting are under FDA review.

Business Segments and Product Lines:

• FNAPT: Prescriptions (TRX) up 25% YoY; New-to-Brand (NBRX) up 18% YoY; launched for Bipolar I disorder with significant expansion (TRX +72%, NBRX +306% since Q2 2024).
• Bisanti: FDA approved Q1 2026 for Bipolar I and Schizophrenia; commercial launch planned for Q4 2026; patents extend to 2044.
• Nereus: Launched May 2026 for motion sickness; Q3 saw >100% growth in prescriptions and prescribers; expanding into GLP-1 induced vomiting via SNDA.
• Hetlios: Maintained market leadership despite generic competition for nearly four years; Q3 sales increased due to specialty pharmacy stocking cycles.
• Ponvori: Sales growth continues; $3 million variable consideration dispute noted from prior periods.
• Pipeline: Dysante Phase 3 enrollment 55% complete; Quimilza BLA under review; Iloperidone LAI program paused pending FDA discussion on PK bridging.

Market and Competitive Landscape:

• FNAPT identified as one of the fastest-growing branded atypical antipsychotics in 2025-2026.
• Hetlios faces ongoing generic competition in the U.S., impacting long-term volume trends.
• Nereus operates in the motion sickness market (cash pay model) and targets a massive, growing GLP-1 patient population for potential expansion.
• Quimilza targets the emerging market for Generalized Pustular Psoriasis (GPP), where few patients are currently under treatment.
• Bisanti positioning leverages a favorable gross-to-net margin (mid-30s) compared to FNAPT (approx. 50%), facilitating a potential franchise transition.

Risks and Challenges:

• Significant revenue headwinds from continued generic competition for Hetlios.
• Operational risks related to manufacturing supply chains for new launches (Nereus, Bisanti, Quimilza).
• Regulatory uncertainty regarding FDA priority review for the Nereus SNDA and potential delays in Quimilza approval.
• Financial risk of higher cash burn in 2026 compared to 2025.
• Legal challenges ongoing against FDA refusals to hold hearings for Hetlios (jet lag) and Nereus (gastroparesis).

Management Commentary and Tone:

• Management expressed confidence in strong revenue momentum and cost moderation, highlighting the conclusion of high-cost Phase 3 and launch prep activities.
• Tone was optimistic regarding the product portfolio expansion, noting the potential to have six approved products by end of 2026.
• Emphasized the strategic value of Bisanti's improved gross-to-net economics and the "life-changing" patient feedback on Nereus.
• Acknowledged the "migration to the mean" in Phase 3 results for Nereus compared to Phase 2 but stressed the robustness of data in severe vomiting cases.
• Stated that the Nereus GLP-1 label is likely to support short-term, incident prevention use rather than chronic maintenance dosing.

Analyst Questions and Answers:

• Quimilza Launch: Management confirmed commercial supplies are being manufactured, targeting market entry in the first half of 2027 pending Dec 12 approval.
• Nereus GLP-1 Efficacy: Explained the gap between Phase 2 (50% reduction) and Phase 3 (27% reduction) results as statistical variability; highlighted 80% reduction in severe cases (>10 vomiting episodes).
• Bisanti Transition: Projected a 3-4 month lag post-launch to see quantifiable revenue shifts from FNAPT to Bisanti due to 90-day prescription lengths; expects FNAPT and Bisanti to be disclosed separately.
• Nereus Pricing/Access: Current motion sickness price set at $255 WAC; future GLP-1 pricing philosophy prioritizes access over immediate high reimbursement, with early payer coverage visible on retail side.
• Dysante MDD: Plans to file for approval based on a single Phase 3 study if positive, leveraging the history of FNAPT/Bisanti approval.
• Quimilza TAM: Estimated several thousand patients in the US with GPP; product offers prevention of flares via IgG4 backbone.

Other Key Points:

• Nereus direct-to-consumer portal (nereus.us) drives early adoption, with patient comments citing "life-changing" experiences.
• A $10 million milestone payment was made to Eli Lilly in Q1 2026 for US Nereus approval.
• The FDA hearing for Hetlios jet lag treatment is scheduled for December 14–18, 2026.
• Vanda is expanding its sales force for FNAPT to ~300 representatives, increasing face-to-face calls by 35% YoY.
• Revenue recognition for Nereus was constrained in Q2 to avoid reversal due to elevated wholesaler inventory.